Related Experiment Video
Updated: Jun 21, 2026
10:14
Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
Published on: May 26, 2023
Type 3 choroidal neovascularization associated with fundus flavimaculatus
Claudia Quijano1, Giuseppe Querques, Nathalie Massamba
1Department of Ophthalmology, Université de Paris XII, Créteil, France.
Ophthalmic Research
|July 25, 2009
Summary
This case study details a patient with fundus flavimaculatus (FFM) and type 3 choroidal neovascularization (CNV). Intravitreal ranibizumab treatment successfully closed the CNV and improved vision.
Area of Science:
- Ophthalmology
- Medical Case Study
- Retinal Diseases
Background:
- Fundus flavimaculatus (FFM) is a rare inherited retinal disorder.
- Type 3 choroidal neovascularization (CNV) involves neovascularization originating from the retinal pigment epithelium.
- The association between FFM and type 3 CNV is not well-documented.
Observation:
- A 78-year-old woman with FFM presented with decreased vision and metamorphopsia.
- Ophthalmologic examination revealed type 3 CNV in the left eye.
- The patient underwent treatment with intravitreal ranibizumab injections.
Findings:
- After three monthly ranibizumab injections, best corrected visual acuity improved from 20/64 to 20/32.
- Fluorescein angiography and indocyanine green angiography confirmed closure of the type 3 CNV.
- Spectral domain optical coherence tomography showed a fibrous scar and resolution of serous retinal detachment.
Implications:
- This is the first reported case of type 3 CNV associated with FFM.
- Intravitreal ranibizumab appears to be a potential therapeutic option for this rare condition.
- Further research is warranted to evaluate the efficacy of ranibizumab in similar cases.
Related Concept Videos
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...